Special Populations
24
Table 5. Vaccinations Prior to or After Solid Organ Transplant
Footnotes
R, recommended—administer if not previously administered or not current; such patients may be at
increased risk for this vaccine-preventable infection
U, usual—administer if patient not current with recommendations for dose(s) of vaccine for
immunocompetent persons in risk and age categories
X, contraindicated.
a
Consider hepatitis B vaccine for hepatitis B-infected liver transplant patients (WR-L).
b
IIV may be administered to SOT recipients despite intensive immunosuppression (eg, during the
immediate posttransplant period), particularly in an outbreak situation (WR-L).
c
Administer only if patient is not immunosuppressed and the timing is ≥4 weeks prior to transplant.
d
Administer only if patient is nonimmune, not severely immunosuppressed, and the timing is
≥4 weeks prior to transplant.
e
For patients ≥19 years who have previously received PPSV23, PCV13 should be administered aer
an interval of ≥1 year aer the last PPSV23 dose (WR-L).
f
Administer only if patient is not immunosuppressed and the timing is ≥4 weeks prior to transplant.*
g
Selected seronegative patients with a renal or liver transplant have been safely vaccinated.*
h
Administer only if patient is not severely immunosuppressed, the timing is ≥4 weeks prior to
transplant, and the patient is varicella-immune as defined by documentation of age-appropriate
varicella vaccination, serologic evidence of immunity, documentation of varicella or zoster infection,
or birth in the United States before 1980. *
i
Administer only if patient is not severely immunosuppressed and the timing is ≥4 weeks prior to
transplant.
* is recommendation deviates from CDC ACIP recommendations.
